Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Laveille

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Pharmaceutical Sciences|April 11, 2000
Use of nonlinear mixed effect modeling for the meta-analysis of preclinical pharmacokinetic data: application to S 20342 in the ratF Bouzom, C Laveille, H Merdjan, et al.
Journal of Clinical Pharmacology|May 20, 1998
Application of population pharmacokinetics to the phase II development of an anti-Alzheimer's disease compound, S12024C Laveille, V Lachaud-Pettiti, E Neuman, et al.
Biometrical Journal. Biometrische Zeitschrift|August 2, 2005
Estimating heterogeneity in random effects models for longitudinal dataA Lemenuel-Diot, A Mallet, C Laveille, et al.
The Journal of Clinical Endocrinology and Metabolism|November 7, 2003
Pharmacodynamics of follicle stimulating hormone (FSH) in postmenopausal women during pulsed estrogen therapy: Evidence that FSH release and synthesis are controlled by distinct pathwaysS Christin-Maitre, C Laveille, J Collette, et al.
Clinical Pharmacology and Therapeutics|September 5, 1998
Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteersI Ragueneau, C Laveille, R Jochemsen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 6, 2000
A pharmacokinetic simulation model for ivabradine in healthy volunteersS B Duffull, S Chabaud, P Nony, et al.
British Journal of Clinical Pharmacology|February 13, 2003
Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulationN Frey, C Laveille, M Paraire, et al.
British Journal of Clinical Pharmacology|August 23, 2007
Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature surveyC Dartois, K Brendel, E Comets, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug DevelopmentM J Swat, S Moodie, S M Wimalaratne, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Pharmaceutical Sciences|April 11, 2000
Use of nonlinear mixed effect modeling for the meta-analysis of preclinical pharmacokinetic data: application to S 20342 in the ratF Bouzom, C Laveille, H Merdjan, et al.
Journal of Clinical Pharmacology|May 20, 1998
Application of population pharmacokinetics to the phase II development of an anti-Alzheimer's disease compound, S12024C Laveille, V Lachaud-Pettiti, E Neuman, et al.
Biometrical Journal. Biometrische Zeitschrift|August 2, 2005
Estimating heterogeneity in random effects models for longitudinal dataA Lemenuel-Diot, A Mallet, C Laveille, et al.
The Journal of Clinical Endocrinology and Metabolism|November 7, 2003
Pharmacodynamics of follicle stimulating hormone (FSH) in postmenopausal women during pulsed estrogen therapy: Evidence that FSH release and synthesis are controlled by distinct pathwaysS Christin-Maitre, C Laveille, J Collette, et al.
Clinical Pharmacology and Therapeutics|September 5, 1998
Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteersI Ragueneau, C Laveille, R Jochemsen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 6, 2000
A pharmacokinetic simulation model for ivabradine in healthy volunteersS B Duffull, S Chabaud, P Nony, et al.
British Journal of Clinical Pharmacology|February 13, 2003
Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulationN Frey, C Laveille, M Paraire, et al.
British Journal of Clinical Pharmacology|August 23, 2007
Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature surveyC Dartois, K Brendel, E Comets, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 31, 2015
Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug DevelopmentM J Swat, S Moodie, S M Wimalaratne, et al.
Pageof 1